Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
Primary Purpose
Inflammation
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Difluprednate Ophthalmic Emulsion
Sponsored by

About this trial
This is an interventional treatment trial for Inflammation
Eligibility Criteria
Inclusion Criteria:
- Patients who have undergone cataract surgery, vitreous surgery or both (including patients who have undergone IOL insertion surgery at the same time)
- Patients showing an anterior chamber cell score of not less than "2" at a day after surgery
- Patients aged 20 years or over, irrespective of genders (it is eligible for enrollment when patients' age attains the criterion on the day of consent obtainment)
Exclusion Criteria:
- Patients who took systemic administration of corticosteroids or immunosuppressive agents, or used ophthalmic ointments of corticosteroids within 1 week before instillation of the investigational drugs;
- Patients who underwent local injection of corticosteroids in the eyes before instillation of the investigational drugs; (patients who used aqueous preparations within 1 week or patient who used depot preparations within 2 weeks were excluded)
- Patients who took systemic administration of non-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 3 days before instillation of the investigational drugs;
- Patients who instilled of corticosteroids, no-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 24 hours before the pre-instillation observation (a day after surgery);
- Patients who underwent perioperative and/or postoperative intravitreous injection of corticosteroids;
- Patients who underwent sub-conjunctival injection or sub-Tenon capsule injection of corticosteroids;
- Patients who have intraocular hemorrhage with a degree that may affect the postoperative evaluations;
- Patients who underwent gas tamponade at the surgery;
- Patients with endogenous uveitis;
- Patients having corneal epithelial detachment or corneal ulcer in the target eye;
- Patients who are suspected of having viral, bacterial or mycotic keratoconjunctival disorders in the target or opposite eye;
- Patients with glaucoma or ocular hypertension, or those with past history of IOP increased due to instillation of corticosteroids, or those whose IOP has been controlled by use of ophthalmic antihypertensive agents;
- Patients showing IOP not less than 25 mmHg a day after surgery;
- Patients who have allergy to corticosteroid drugs;
- Patients who are required to wear contact lens during the study period;
- Patients who are scheduled to undergo surgery of the opposite eye during the study period;
- Patients who are pregnant or may be pregnant or lactating;
- Patients who have participated in other clinical studies within 3 months.
Sites / Locations
Outcomes
Primary Outcome Measures
The changes in anterior chamber cell score at day 14 after start of instillation from the baseline level (differences from the baseline score) were compared between the 2 treatment groups.
Secondary Outcome Measures
The changes in anterior chamber cell score at days 3 and 7 after start of instillation were compared between the 2 treatment groups.
The numbers of patients showing an anterior chamber cell score of "0" at days 3, 7 and 14 after start of instillation were compared between the 2 treatment groups.
The changes in anterior chamber flare score at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.
The changes in the total scores of subjective symptoms and objective signs at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.
Full Information
NCT ID
NCT00406341
First Posted
November 29, 2006
Last Updated
November 29, 2006
Sponsor
Sirion Therapeutics, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00406341
Brief Title
Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
Official Title
Phase 3 Confimatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treament of Postoperative Inflammation
Study Type
Interventional
2. Study Status
Record Verification Date
November 2006
Overall Recruitment Status
Completed
Study Start Date
April 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2005 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Sirion Therapeutics, Inc.
4. Oversight
5. Study Description
Brief Summary
The purpose of this phase 3 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.
Detailed Description
The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion in patients with intraocular postoperative inflammation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
200 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Difluprednate Ophthalmic Emulsion
Primary Outcome Measure Information:
Title
The changes in anterior chamber cell score at day 14 after start of instillation from the baseline level (differences from the baseline score) were compared between the 2 treatment groups.
Secondary Outcome Measure Information:
Title
The changes in anterior chamber cell score at days 3 and 7 after start of instillation were compared between the 2 treatment groups.
Title
The numbers of patients showing an anterior chamber cell score of "0" at days 3, 7 and 14 after start of instillation were compared between the 2 treatment groups.
Title
The changes in anterior chamber flare score at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.
Title
The changes in the total scores of subjective symptoms and objective signs at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who have undergone cataract surgery, vitreous surgery or both (including patients who have undergone IOL insertion surgery at the same time)
Patients showing an anterior chamber cell score of not less than "2" at a day after surgery
Patients aged 20 years or over, irrespective of genders (it is eligible for enrollment when patients' age attains the criterion on the day of consent obtainment)
Exclusion Criteria:
Patients who took systemic administration of corticosteroids or immunosuppressive agents, or used ophthalmic ointments of corticosteroids within 1 week before instillation of the investigational drugs;
Patients who underwent local injection of corticosteroids in the eyes before instillation of the investigational drugs; (patients who used aqueous preparations within 1 week or patient who used depot preparations within 2 weeks were excluded)
Patients who took systemic administration of non-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 3 days before instillation of the investigational drugs;
Patients who instilled of corticosteroids, no-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 24 hours before the pre-instillation observation (a day after surgery);
Patients who underwent perioperative and/or postoperative intravitreous injection of corticosteroids;
Patients who underwent sub-conjunctival injection or sub-Tenon capsule injection of corticosteroids;
Patients who have intraocular hemorrhage with a degree that may affect the postoperative evaluations;
Patients who underwent gas tamponade at the surgery;
Patients with endogenous uveitis;
Patients having corneal epithelial detachment or corneal ulcer in the target eye;
Patients who are suspected of having viral, bacterial or mycotic keratoconjunctival disorders in the target or opposite eye;
Patients with glaucoma or ocular hypertension, or those with past history of IOP increased due to instillation of corticosteroids, or those whose IOP has been controlled by use of ophthalmic antihypertensive agents;
Patients showing IOP not less than 25 mmHg a day after surgery;
Patients who have allergy to corticosteroid drugs;
Patients who are required to wear contact lens during the study period;
Patients who are scheduled to undergo surgery of the opposite eye during the study period;
Patients who are pregnant or may be pregnant or lactating;
Patients who have participated in other clinical studies within 3 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shigeaki Ohno
Organizational Affiliation
Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Hokkaido University
Official's Role
Study Chair
12. IPD Sharing Statement
Learn more about this trial
Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
We'll reach out to this number within 24 hrs